Engineered knockout cell lysates for reproducible proteomic analysis
Cambridge, UK, 7th November 2019 – Abcam’s new engineered knockout cell lysates enable proteomic studies by providing researchers with “true negative” controls.
Acquiring reliable off-the-shelf knockout mouse models or cell lines that match specific experimental requirements can be challenging, and often need to be sourced directly from individual researchers or labs. Abcam’s newly-launched collection addresses this issue by providing access to over 2,800 diploid KO cell lysates, the largest selection currently available to researchers.
The lysates are useful for studies requiring loss-of-function phenotypes at the proteomic level as well as routine applications such as Western blotting and mass spectroscopy. They also can be used to support antibody and target validation. The use of diploid cells makes the lysates well suited to the more complex studies often carried out in cancer research.
Derived from commonly used immortalized cell lines, KO lysates have been engineered using CRISPR-Cas9 and are accompanied by Sanger sequencing and Western blotting validation data. Corresponding wild-type controls are also provided so that the biological impact of each KO lysate can easily be assessed within a consistent cellular background.
Abcam’s KO cell lysates deliver:
- Access to thousands of CRISPR-Cas9-engineered KO cell lysates of interest, without needing to generate or purchase a KO cell line, saving on average 4–12 weeks’ work in the lab
- Minimal preparation required
- Diploid KO lysates derived from commonly used cell lines including HeLa, HEK293T, A549, HCT116, Hep G2 and MCF
Abcam Human TOMM34 KO HeLa Cell Lysate Refrigerated and Frozen Shipping Systems
Abcam Human TOMM34 KO HeLa Cell Lysate x2
Please contact firstname.lastname@example.org for any high resolution images of the product.
- ENDS -
Notes To Editors
About Abcam plc
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading, antibody expertise. By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products. With eleven sites globally, many of Abcam's 1,100 strong team are located in the world's leading life science research hubs, complementing a global network of services and support.
To find out more, please visit www.abcam.com and www.abcamplc.com.
Issued for and on behalf of Abcam plc by Instinctif Partners.
For more information please contact:
Dr Priya Kalia
At Instinctif Partners:
Tim Watson / Dr Katie Duffell
T: +44 (0)20 7457 2013